The Cancer Screening Market in China (2018-2023) by End-User, Screening Type and Application - Quest Diagnostics, Hologic, Qiagen, F. Hoffmann-La Roche, and Abbott Laboratories are Dominating - ResearchAndMarkets.com

The "Cancer Screening Market in China (2018-2023)" report has been added to ResearchAndMarkets.com's offering.

The cancer screening market in China is expected to reach USD 1.5 billion by 2023, growing at a CAGR of 14% from 2018.

China's demand for cancer screening has grown at a fast pace in the past decade. Cancer is one of the most significant healthcare burdens in China. The Chinese economy maintains a high pace of growth stimulated by the consecutive increase in capital investment.

Key Growth Factors

Rise in the population along with an increase in the patient pool and favourable government policies is a key driver for the market. Also, there is an increase in the aging population, growing levels of pollution and a more sedentary lifestyle.

Threats

Providing drugs at lower prices along with ensuring affordability as well as accessibility will be a major threat for the region. Transparency in medical treatment is being been demanded by people, hence, provision of accurate and proper treatment will be a disguised opportunity.

Key Players Profiled

• Quest Diagnostics
• Hologic
• Qiagen
• F. Hoffmann-La Roche
• Abbott Laboratories

Topics Covered

Chapter 1: Executive Summary

Chapter 2: Cancer Screening Market in China - Market Overview

Chapter 3: Cancer Screening Market in China - by End-User

Chapter 4: Cancer Screening Market in China - by Screening Type

Chapter 5: Cancer Screening Market in China - by Application

Chapter 6: Competitive Landscape

Chapter 7: Conclusion

For more information about this report visit https://www.researchandmarkets.com/research/gdl875/the_cancer?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181212005366/en/